Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Chronic Obstructive Pulmonary Disease: Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Pathophysiology:
2.7 Treatment and Management Patterns
2.8 GlobalData Pipeline Report Guidance

3 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Market Characterization
3.1 COPD Therapeutics Market Size (2005-2010) - Global
3.2 COPD Therapeutics Market Forecast (2010-2018) - Global
3.3 COPD Therapeutics Market Size (2005-2010) - The US
3.4 COPD Therapeutics Market Forecast (2010-2018) - The US
3.5 COPD Therapeutics Market Size (2005-2010) - France
3.6 COPD Therapeutics Market Forecast (2010-2018) - France
3.7 COPD Therapeutics Market Size (2005-2010) - Germany
3.8 COPD Therapeutics Market Forecast (2010-2018) - Germany
3.9 COPD Therapeutics Market Size (2005-2010) - Italy
3.10 COPD Therapeutics Market Forecast (2010-2018) - Italy
3.11 COPD Therapeutics Market Size (2005-2010) - Spain
3.12 COPD Therapeutics Market Forecast (2010-2018) - Spain
3.13 COPD Therapeutics Market Size (2005-2010) - The UK
3.14 COPD Therapeutics Market Forecast (2010-2018) - The UK
3.15 COPD Therapeutics Market Size (2005-2010) - Japan
3.16 COPD Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the COPD Therapeutics Market
3.17.1 Drivers for the COPD Therapeutics Market
3.17.2 Barriers for the COPD Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the COPD Therapeutics Market
4.3.1 Spiriva® HandiHaler® (tiotropium bromide inhalation powder)
4.3.2 Brovana (arformoterol)
4.3.3 Foradil® Aerolizer™ (formoterol fumarate inhalation powder)
4.3.4 Symbicort (budesonide/formoterol fumarate dihydrate) 160/4.5µg
4.3.5 Advair Diskus (fluticasone propionate/salmeterol) 250/50µg
4.3.6 Arcapta/Onbrez® Breezhaler® (indacaterol maleate)
4.3.7 Daliresp (roflumilast) Tablet
4.3.8 Atrovent HFA (ipratropium bromide)
4.3.9 Combivent (ipratropium bromide and albuterol sulfate)
4.4 Key Takeaway

5 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 COPD Pipeline - Pipeline by Phases of Development
5.3.1 COPD Therapeutics - NDA Filed
5.3.2 COPD Therapeutics - Phase III Pipeline
5.3.3 COPD Therapeutics - Phase II Pipeline
5.3.4 COPD Therapeutics - Phase I Pipeline
5.3.5 COPD Therapeutics - Preclinical Pipeline
5.3.6 COPD Therapeutics - Discovery Pipeline
5.4 COPD Therapeutics - Pipeline by Mechanism of Action
5.4.1 Technology Trends Analytic Framework
5.5 COPD Therapeutics - Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Eklira (aclidinium bromide)
5.6.2 Andolast (CR 2039)
5.6.3 Dulera
5.6.4 Erdosteine
5.6.5 Fluticasone + Formoterol
5.6.6 Glycopyrronium bromide (NVA237)
5.6.7 GSK573719
5.6.8 Olodaterol (BI 1744 CL)
5.6.9 QVA 149 (indacaterol and glycopyrrolate)
5.6.10 Relovair
5.6.11 Vilanterol (GW642444)
5.6.12 Vilanterol + GSK573719
5.6.13 Easyhaler Inhalation Corticosteroid/Beta Agonist Fixed Dose Combination
5.7 Key Takeaway

6 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in COPD Therapeutics Clinical Trials

7 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 COPD Therapeutics: Implications for Future Market Competition

8 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 GlaxoSmithKline plc
8.2.2 Novartis AG
8.2.3 AstraZeneca PLC
8.2.4 Merck & Co., Inc.
8.2.5 Forest Laboratories, Inc.
8.2.6 Boehringer Ingelheim GmbH
8.2.7 Almirall, S.A.
8.2.8 Orion Corporation
8.2.9 Rottapharm Madaus
8.2.10 Ache Laboratorios Farmaceuticos S/A
8.2.11 Other Companies in the COPD therapeutics market

9 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Licensing and Partnership Deals

10 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

List of Tables

Table 1: GOLD Disease Stratification Guidelines for Severity of COPD
Table 2: COPD Epidemiology in Major Markets, 2011
Table 3: COPD Therapeutics Market, Global, Revenue ($bn), 2005-2010
Table 4: COPD Therapeutics Market, Global, Forecasts ($bn), 2010-2018
Table 5: COPD Therapeutics Market, The US, Revenue ($bn), 2005-2010
Table 6: COPD Therapeutics Market, The US, Forecasts ($bn), 2010-2018
Table 7: COPD Therapeutics Market, France, Revenue ($m), 2005-2010
Table 8: COPD Therapeutics Market, France, Forecasts ($m), 2010-2018
Table 9: COPD Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 10: COPD Therapeutics Market, Germany, Forecasts ($m), 2010-2018
Table 11: COPD Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 12: COPD Therapeutics Market, Italy, Forecasts ($m), 2010-2018
Table 13: COPD Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 14: COPD Therapeutics Market, Spain, Forecasts ($m), 2010-2018
Table 15: COPD Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 16: COPD Therapeutics Market, the UK, Forecasts ($m), 2010-2018
Table 17: COPD Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 18: COPD Therapeutics Market, Japan, Forecasts ($m), 2010-2018
Table 19: COPD Therapeutics - NDA Filed, 2011
Table 20: COPD Therapeutics - Phase III Pipeline, 2011
Table 21: COPD Therapeutics - Phase II Pipeline, 2011
Table 22: COPD Therapeutics - Phase I Pipeline, 2011
Table 23: COPD Therapeutics - Preclinical Pipeline, 2011
Table 24: COPD Therapeutics - Discovery Pipeline, 2011
Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart
Table 26: COPD Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 27: COPD Therapeutics - Clinical Trials by Country, 2011
Table 28: COPD Therapeutics - Clinical Trials by Phase, 2011
Table 29: COPD Therapeutics - Clinical Trials by Status, 2011
Table 30: COPD Therapeutics - Overall Sponsors, 2011
Table 31: COPD Therapeutics -Prominent Sponsors, 2011
Table 32: COPD Therapeutics: Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 33: GlaxoSmithKline plc- Respiratory pipeline 2011
Table 34: GlaxoSmithKline plc- COPD pipeline 2011
Table 35: GlaxoSmithKline plc - Deals
Table 36: Novartis AG - Respiratory pipeline
Table 37: Novartis AG COPD Pipeline
Table 38: Novartis AG - Deals
Table 39: AstraZeneca PLC - Respiratory Pipeline
Table 40: AstraZeneca PLC - COPD Pipeline, 2011
Table 41: AstraZeneca PLC - Deals
Table 42: Merck & Co., Inc. - Respiratory pipeline, 2011
Table 43: Merck & Co., Inc. - COPD Pipeline, 2011
Table 44: Merck & Co., Inc. - Deals, 2011
Table 45: Forest Laboratories, Inc. - Respiratory pipeline, 2011
Table 46: Forest Laboratories, Inc. - Deals, 2011
Table 47: Boehringer Ingelheim GmbH - Respiratory Pipeline, 2011
Table 48: Boehringer Ingelheim GmbH - COPD Pipeline, 2011
Table 49: Boehringer Ingelheim GmbH - Deals
Table 50: Almirall, S.A. - Respiratory Pipeline, 2011
Table 51: Almirall, S.A. - Deals, 2011
Table 52: Orion Corporation - Respiratory Pipeline, 2011
Table 53: Orion Corporation - Deals, 2011
Table 54: Rottapharm Madaus - Respiratory Pipeline, 2011
Table 55: Rottapharm Madaus - COPD Pipeline, 2011
Table 56: Rottapharm Madaus - Deals, 2011
Table 57: Ache Laboratorios Farmaceuticos S/A - Respiratory Pipeline, 2011
Table 58: Ache Laboratorios Farmaceuticos S/A - Deals, 2011
Table 59: COPD therapeutics market - Other Future Players, 2011
Table 60: COPD Therapeutics, Licensing and Partnership Deals, 2011

List of Figures

Figure 1: COPD - Disease Characterization
Figure 2: COPD Treatment Algorithm
Figure 3: COPD Therapeutics Market, Global, Revenue ($bn), 2005-2010
Figure 4: COPD Therapeutics, Market Share (%), 2010
Figure 5: COPD Therapeutics Market, Global, Forecasts ($bn), 2010-2018
Figure 6: COPD Therapeutics, Market Share (%), 2018
Figure 7: COPD Therapeutics Market, The US, Revenue ($bn), 2005-2010
Figure 8: COPD Therapeutics Market, The US, Forecasts ($bn), 2010-2018
Figure 9: COPD Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 10: COPD Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 11: COPD Therapeutics Market, Germany , Revenue ($m), 2005-2010
Figure 12: COPD Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 13: COPD Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 14: COPD Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 15: COPD Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 16: COPD Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 17: COPD Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 18: COPD Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 19: COPD Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 20: COPD Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 21: Opportunity and Unmet Need in the COPD Therapeutics Market, 2011
Figure 22: COPD Therapeutics - Strategic Competitor Assessment, 2011
Figure 23: COPD - Pipeline by Phase of Development, 2011
Figure 24: COPD Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011
Figure 25: COPD Therapeutics - Technology Trends Analytics Framework, 2011
Figure 26: COPD Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 27: COPD Therapeutics - Clinical Trials by Country, 2011
Figure 28: COPD Therapeutics - Clinical Trials by Phase, 2011
Figure 29: COPD Therapeutics - Clinical Trials by Status, 2011
Figure 30: COPD Therapeutics - Overall Sponsors, 2011
Figure 31: COPD Therapeutics - Prominent Sponsors, 2011
Figure 32: COPD Therapeutics - Top Companies Participating in Clinical Trials, 2011
Figure 33: COPD Market, Drivers and Restraints 2011
Figure 34: Implications for Future Market Competition in COPD Therapeutics Market, 2011
Figure 35: COPD - Pipeline by Company, 2011
Figure 36: GlobalData Market Forecasting Model